A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Takeda
Fusion Pharmaceuticals Inc.
Tempus AI
Actym Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Bolt Biotherapeutics, Inc.
Elevation Oncology
Turnstone Biologics, Corp.
Aminex Therapeutics, Inc.
NantCell, Inc.
Ikena Oncology
Eisai Inc.
CytomX Therapeutics
Fusion Pharmaceuticals Inc.
Fate Therapeutics
Oncorus, Inc.
MacroGenics
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Dartmouth-Hitchcock Medical Center
Seagen Inc.
CureOne
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
sigma-tau i.f.r. S.p.A.
University of Pittsburgh
University Health Network, Toronto
Masonic Cancer Center, University of Minnesota
Otsuka Novel Products GmbH
Sir Mortimer B. Davis - Jewish General Hospital
Calando Pharmaceuticals
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center